FATE THERAPEUTICS INC Shareholders' Equity
FATE THERAPEUTICS INC (FATE) had Shareholders' Equity of $153.44 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $153.44M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $179.71M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $207.18M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $234.07M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $153.44M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $179.71M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $207.18M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $234.07M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $261.36M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $288.41M 10-Q · filed 2026-08-13 |
| 2024-12-31 | $318.73M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $362.33M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $396.98M 10-Q · filed 2025-11-13 |
| 2024-03-31 | $426.12M 10-Q · filed 2025-11-13 |
| 2023-12-31 | $368.42M 10-K · filed 2026-02-26 |
| 2023-09-30 | $402.78M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $437.75M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $477.47M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $483.94M 10-K · filed 2025-03-05 |
| 2022-09-30 | $518.00M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $580.48M 10-Q · filed 2023-11-08 |
| 2022-03-31 | $633.39M 10-Q · filed 2023-11-08 |
| 2021-12-31 | $678.84M 10-K · filed 2024-02-26 |
| 2021-09-30 | $730.33M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $752.07M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $790.10M 10-Q · filed 2022-11-03 |
| 2020-12-31 | $384.44M 10-K · filed 2023-02-28 |
| 2020-09-30 | $424.37M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $474.11M 10-Q · filed 2021-11-04 |
| 2020-03-31 | $219.22M 10-Q · filed 2021-11-04 |
| 2019-12-31 | $244.76M 10-K · filed 2023-02-28 |
| 2019-09-30 | $268.04M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $127.53M 10-Q · filed 2020-11-05 |
| 2019-03-31 | $145.84M 10-Q · filed 2020-11-05 |
| 2018-12-31 | $160.47M 10-K · filed 2022-02-28 |
| 2018-09-30 | $173.93M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $51.83M 10-Q · filed 2019-11-05 |
| 2018-03-31 | $65.00M 10-Q · filed 2019-11-05 |
| 2017-12-31 | $77.19M 10-K · filed 2021-02-24 |
| 2017-09-30 | $45.75M 10-Q · filed 2018-11-01 |
| 2017-06-30 | $55.21M 10-Q · filed 2018-11-01 |
| 2017-03-31 | $63.86M 10-Q · filed 2018-11-01 |
| 2016-12-31 | $73.15M 10-K · filed 2020-03-02 |
| 2016-09-30 | $25.37M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $23.13M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $30.73M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $38.04M 10-K · filed 2019-03-05 |
| 2015-09-30 | $44.99M 10-Q · filed 2015-11-03 |
| 2015-06-30 | $51.07M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $21.25M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $28.34M 10-K · filed 2018-03-05 |
| 2014-09-30 | $33.58M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $39.64M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $45.18M 10-Q · filed 2014-05-13 |
| 2013-12-31 | $50.85M 10-K · filed 2017-03-16 |
| 2013-09-30 | -$66.40M 10-Q · filed 2013-11-13 |
| 2012-12-31 | -$52.83M 10-K · filed 2016-03-03 |
| 2011-12-31 | -$50.68M 10-K · filed 2015-03-12 |
| 2010-12-31 | -$37.44M 10-K · filed 2014-03-17 |
| 2009-12-31 | -$21.46M 10-K · filed 2014-03-17 |
| 2008-12-31 | -$8.35M 10-K · filed 2014-03-17 |
| 2007-12-31 | -$1.22M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |